PrintThe Burrill Report
The Burrill Report (February 6, 2012): Fixing Drug Development with the Wisdom of Crowds (.MP3,14.48 Mb)
Transparency Life Sciences is betting on the wisdom of crowds when it comes to designing clinical trials. The company believes that it can address problems of falling R&D productivity that have plagued the pharmaceutical industry by using crowdsourcing and digital health technologies to design and conduct clinical trials more efficiently. We spoke to Tomasz Sablinski, CEO of Transparency, about what’s broken in drug development today, what his company is doing to change traditional approaches, and what need to do to prove its model actually works.
February 04, 2012
http://www.burrillreport.com/article-fixing_drug_development_with_the_wisdom_of_crowds.html
BUSINESS STRATEGY
Fixing Drug Development with the Wisdom of Crowds
Podcast: February 6, 2012[Please login to post comments]
- AstraZeneca Axes 7,300 Jobs, 12 Percent of Workforce
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - FDA, Industry Urge Quick Passage of User Fee Renewal
First House hearing on PDUFA V skips fireworks, reflects general harmony. Read More - Federal Spending on Healthcare to Double by 2022
CBO warns policymakers will need to curb healthcare spending, grow revenue. Read More - Medical Device Makers Trade Higher Fees Faster Review Times
Regulators and industry reach agreement in principle on reauthorization of MDUFA. Read More - Big Pharma Declares War on Neglected Diseases
Partners pledge to coordinate efforts to accelerate progress. Read More - Two Life Sciences IPOs Debut Below Target
The arrival of Facebookâs long-awaited filing could encourage more companies to go public. Read More - E-Prescriptions Could Improve Patient Adherence
New study shows potential to reduce healthcare expenditures by $240 billion. Read More - Drug Supplies and Economics 101
Artificially low drug prices cause shortages. Read More - Americans Warming to Healthcare Reform Law
Survey finds Americans still divided over the legislation, but support for certain components slowly increasing. Read More - What's Driving Roche's $5.7 Billion Bid for Illumina
Podcast: January 30, 2012 Read More
.gif)
